• Mashup Score: 0

    Behavioral science is being applied in unique ways for enterprise imaging product design. Involving clinicians in the product design process has led Change Healthcare to completely re-architect a new-generation hemodynamic solution. By listening to key stakeholders, new features are being brought to market that will have notable impact on the way health systems operate. By building better…

    Tweet Tweets with this article
    • @DAICeditor @Change_HC @NMMC_news #Behavioralscience is being applied in unique ways for #enterprise_imaging product design; involving #clinicians in the has led Change Healthcare to completely re-architect a new-generation #hemodynamic solution: https://t.co/nlu55DayPa

  • Mashup Score: 1

    Moderator: Daniel J. Cole, MD, Professor of Clinical Anesthesiology, and Vice Chair for Professional and Business Development, Anesthesiology, University of California, Los Angeles, Los Angeles, CA Daniel J. Cole, MD, earned his Doctor of Medicine degree from Loma Linda University, where he also completed his residency in anesthesiology. He completed a neuroscience research fellowship at the…

    Tweet Tweets with this article
    • RT @iars360: 1 Week to Register! Fixing Hemodynamic Instability Webinar - https://t.co/nwddoPvOMP #Hemodynamic stability is common, known t…

  • Mashup Score: 0

    March 24, 2023 — Abbott announced new data that found monitoring patients remotely with hemodynamic pressure sensing technology, such as with its CardioMEMS HF System, can significantly1 improve survival in heart failure patients with reduced ejection fraction (HFrEF). The analysis is the first to give doctors specific insight into how remotely monitoring patients with technology like CardioMEMS…

    Tweet Tweets with this article
    • @DAICeditor @AbbottCardio Abbott announced new data that found monitoring #patients remotely with #hemodynamic pressure sensing #technology can significantly improve survival in #heartfailure patients with reduced ejection fraction (#HFrEF): https://t.co/ZbfPZN6oUx

  • Mashup Score: 6

    Sign Up for Our NewsletterGet the latest news and information from CRF.By submitting your email address, you agree to CRF’s Privacy Policy & Terms and Conditions.1700 Broadway, 9th FloorNew York, NY 10019646.434.4500[email protected]© 2023, Cardiovascular Research Foundation. All rights reserved.Privacy PolicyTerms and Conditions of Use

    Tweet Tweets with this article
    • Hone your skills on how and why to perform invasive #hemodynamic exercise testing and how to interpret the results for optimal phenotyping of #heartfailure. Today at 2:00 PM. #THT2023 https://t.co/LoPQ5iB6eg @StavrosDrakos @JenHoCardiology @HFpEF @RyanTedfordMD @BurkhoffMd https://t.co/JJ5aWiGDhc

  • Mashup Score: 3

    Sign Up for Our NewsletterGet the latest news and information from CRF.By submitting your email address, you agree to CRF’s Privacy Policy & Terms and Conditions.1700 Broadway, 9th FloorNew York, NY 10019646.434.4500[email protected]© 2023, Cardiovascular Research Foundation. All rights reserved.Privacy PolicyTerms and Conditions of Use

    Tweet Tweets with this article
    • Hone your skills on how and why to perform invasive #hemodynamic exercise testing, and how to interpret the results for optimal phenotyping of #heartfailure. Tuesday, 3/21, 2:00 PM. Only at #THT2023! https://t.co/1N01wuRgKR @StavrosDrakos @JenHoCardiology @HFpEF @RyanTedfordMD… https://t.co/9nX26P4E0Z https://t.co/YpDHOKHhMK

  • Mashup Score: 0

    Selexipag improved pulmonary vascular resistance and other hemodynamic variables among patients with chronic thromboembolic pulmonary hypertension, according to results published in European Respiratory Journal.However, there was no change in exercise capacity after treatment.

    Tweet Tweets with this article
    • Selexipag treatment improved pulmonary vascular resistance and other #hemodynamic variables in patients with CTEPH in randomized study published in @ERSpublications @CardiologyToday https://t.co/uzKKa8NEtA

  • Mashup Score: 0

    Selexipag improved pulmonary vascular resistance and other hemodynamic variables among patients with chronic thromboembolic pulmonary hypertension, according to results published in European Respiratory Journal.However, there was no change in exercise capacity after treatment.

    Tweet Tweets with this article
    • Selexipag treatment improved pulmonary vascular resistance and other #hemodynamic variables in patients with CTEPH in randomized study published in @ERSpublications @CardiologyToday https://t.co/zGVU4UWFDm

    • Selexipag treatment improved pulmonary vascular resistance and other #hemodynamic variables in patients with CTEPH in randomized study published in @ERSpublications @CardiologyToday https://t.co/M89yVEyk58